We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brett King

Brett King MD, PhD

Associate Professor of Dermatology, Yale School of Medicine, New Haven, Connecticut

Brett King is Associate Professor of Dermatology at Yale University School of Medicine, specializing in treatment of inflammatory skin diseases. Dr King has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, and his work has revealed the broad utility of JAK inhibitors for the treatment of inflammatory skin disease, including alopecia areata, vitiligo, and atopic dermatitis, as well as other conditions. He has lectured nationally and internationally and published numerous articles on this and other topics. Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.

Disclosures

Dr. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for Aclaris Therapeutics Inc, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Pfizer Inc, TWi Biotechnology Inc, and Viela Bio.